Advertisement

Nucleoside Transport Protein: Properties and Regulation

  • Anwar S. A. Abd-Elfattah
  • Samir Mardini
  • Jian-Hua Guo
  • Mohanad I. Shehab
  • Nashaat El-Singaby
  • Shin-Ping Gao
  • El-Mostafa El-Guessab
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 181)

Abstract

Membrane-bound purinergic receptors mediate several physiological responses of adenine nucleotides and nucleosides. These receptors are located on the external side of the plasma membranes. For example, adenosine receptor activation and subsequent signal transduction is determined by the concentration of the ligand in the vicinity of the receptor. Therefore, adenosine transport (release and uptake) via nucleoside transporters, phosphorylation by adenosine kinase and deamination play a significant role in the degree by which adenosine receptors are activated. Extracellular ATP activates purinegic receptors (P2) while ATP uptake (1,2) and dephosphorylation by ecto-nucleotidases result in termination of receptor activation. On the other hand, nucleosides produced inside the cell during ischemic and hypoxic stress must be removed from the intracellular domain either by a transport mechanism or by incorporation into the salvage pathway of nucleotides inside cells. Therefore, a bidirectional nucleoside transporter is necessary for regulation of nucleoside uptake and release during normal and pathophysiologic conditions. This Chapter will cover the historical aspects of the discovery and characterization of adenine nucleoside transporters in different cell models in general and in cardiac muscle in particular.

Keywords

Adenine Nucleotide Adenosine Deaminase Myocardial Stunning Nucleoside Transport Endogenous Adenosine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chaudry IH, Clements MG, Baue AE. Uptake of ATP by tissues. In: Stone TW, editor, Purines: Pharmacology and Physiological Roles. MacMillan Press, London; 1985.Google Scholar
  2. 2.
    El-Moatassim C, Berbard N, Mani JC, Dornand J. Extracellular ATP induces a nonspecific permeability of thymocyte plasm membranes. Biochem Cell Biol 1989;67:495–502.PubMedCrossRefGoogle Scholar
  3. 3.
    Paterson ARP, Jakobs ES, Ng CYC, Odegard RD, Adjei AA Transport of nucleoside drugs in animal cells. In:Goldman ID, ed. Membrane Transport of Antineoplastic Agents. New York: Pergamon Press, 1986; 309–329.Google Scholar
  4. 4.
    Paterson ARP, Jakobs ES, NG CYC, Odegard RD, Adjei AA Nucleoside transport inhibition in vitro and in vivo. In: Gerlach E, Becker BF, editors, Topics and Perspectives in Adenosine Research. Berlin: Springer-Verlag, 11987;89–101.Google Scholar
  5. 5.
    Paterson ARP, Clanachan AS, Crick JD, Gati WP, Jakobs ES, Wiely JS, Cassi CE: Plasma membrane transport of nucleosides, nucleobases and nucleotides: an overview. In Imai S, Nakazawa M, edis. Role of adenosine and adenine nucleotides in the biological systems. 1991, Elsevier Science Publishers BV, Amesterdam, New York, pp 133–149.Google Scholar
  6. 6.
    Javris SM, Young JD. Photoaffinity labelling of nucleoside transporter polypeptide. Pharmacol Ther 1987;32:339–359.CrossRefGoogle Scholar
  7. 7.
    Jarvis SM, Williams TC, Lee CW, Cheeseman CI. Active transport of nucleosides and drugs. Biochem Soc Trans 1989;17:448–450.PubMedGoogle Scholar
  8. 8.
    Jarvis SM.: Nitrobenzylthioinosine-sensitive nucleoside system: mechanisms of inhibition by dipyridamole. Mol Pharmacol 1989; 30:659–665.Google Scholar
  9. 9.
    Kwong FPY, Davis A, Tse CM, Young JD, Henderson PJF, Baldwin SA Purification of human erythrocyte nucleoside transporter by immunoaffinity chromatography. Biochem J 1988; 255:243–249.PubMedGoogle Scholar
  10. 10.
    Aganyo FR, Vijayalakshim D, Criak JD, Gati WP, McAdam DP, Asakura J, Robinson MJ, Paterson ARP, Cass CE. SAENTA, a novel ligand with high affinity for polypeptide associated with nucleoside transport: partial purification of the nitrobenzylthioinosine-binding protein of pig erythrocytes by affinity chromatography. Biochem J 1990;270:605–614.Google Scholar
  11. 11.
    Agbanyo FR, Cass CE, Paterson ARP. External location of sites on pig erythrocyte membranes that bind nitrobenzylthioinosine. Mol Pharmacol 1988;3:332–337.Google Scholar
  12. 12.
    Wiley JS, Brocklebank AM, Snook MB, Jamieson GB, Sawyer WH, Ceaik JD, Cass CE, RobinsMJ, McAdam DP, Paterson ARP. SAENTA-X2-fluroscein: A fluorescent probe for the equilibrative, inhibitor-sensitive nucleoside transporter. Biochem J 1991;273:667–672.PubMedGoogle Scholar
  13. 13.
    Jarvis SM: Nitrobenzylthioinoisne-sensitive nucleoside transport system: mechanisms of inhibition by dipyridamole. Mol Pharmacol 1986;30:659–665.PubMedGoogle Scholar
  14. 14.
    Plagemann PGW, Wohlhueter RM, Woffendin C: Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 1988;947:405–443.PubMedGoogle Scholar
  15. 15.
    Plagemann PGW, Kraupp M. Inhibition of nucleoside nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine. Biochem Pharmacol 1986;35:2559–2567.PubMedCrossRefGoogle Scholar
  16. 16.
    Plagemann PGW, Woffendin C. Species differences in sensitivity of nucleoside transport in erythrocytes and culture cells to inhibition by nitrobenzylthioinosine, dipyridamole, dilazep and lidoflazine. Biochim Biophys Acta 1988;969:1–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Gati WP, Paterson: Interaction of [3H]dilazep at nucleoside transporter-associated binding sites on S49 mouse lymphoma cell. Mol Pharmacol 1989;36:134–141.PubMedGoogle Scholar
  18. 18.
    Gati W P, Paterson ARP. Nucleoside transport. In: Agre P, Parker JC, editors, Red Blood Cell Membranes, Structure, Function, Clinical Implications, Marcel Dekker, Inc., 1989, pp. 635–661.Google Scholar
  19. 19.
    Cass CE, Gaudette LA, Paterson ARP. Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor of nitrobensyl-thioinosine to nucleoside transport sites in the erythrocyte membrane. Biochim Biophys Acta 1974;345:1–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Oliver JM, Paterson ARP. Nucleoside transport. I. A mediated process in human erythrocytes. Can J Biochem 1971;49:262–270.Google Scholar
  21. 21.
    Jarvis SM, Williams TC, Lee CW, Cheeseman CI. Active transport of nucleosides and drugs. Biochem Soc Trans 1989;17:448–450.PubMedGoogle Scholar
  22. 22.
    Paterson ARP, Paran JH, Yang S, Lynch TP. Protection of mice against lethal dosages of nebularine by nitrobenzylthioinosine, and inhibitor of nucleoside transport. Cancer Res 1979;39:515–536.Google Scholar
  23. 23.
    Williams EF, Barker PH, Clanachan AS. Nucleoside transport in heart: species differences in nitrobenzylthioinosine binding, adenosine accumulation, and drug-induced potentiation of adenosine action. Can J Physiol Pharmacol 1984;62:31–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Hammond JR, Clanachan AS: Species differences in the binding of [HJnitrobenzylthioinosine to the nucleoside transport system in mammalian central nervous system membranes: Evidence for inercovertible conformations of the biding site/transporter complex. J Neurochemi 1985;45:537–535.Google Scholar
  25. 25.
    Abd-Elfattah AS, Jessen ME, Lekven J, Doherty NE III, Brunsting LA, Wechsler AS: Myocardial reperfusion injury: Role of myocardial hypoxanthine and xanthine on free- radical-mediated reperfusion injury. Circulation 1988;78(Suppl III):224–235.Google Scholar
  26. 26.
    Abd-Elfattah AS, Jessen ME, Hanan SA, Tuchy G, Wechsler AS: Is adenosine-5′- triphosphate derangement or free-radical-mediated injury the major cause of ventricular dysfunction during reperfusion? Role of adenine nucleoside transport in myocardial reperfusion injury. Circulation 1990;82(suppl IV):IV-341–350.Google Scholar
  27. 27.
    Abd-Elfattah AS, Wechsler AS: Separation between ischemic and reperfusion injury by site specific entrapment of endogenous adenosine and inosine using NBMPR and EHNA. J Card Surg 1994;9[Suppl]:387–396.PubMedGoogle Scholar
  28. 28.
    Abd-Elfattah AS, Messier RH Jr., Domkowski MS, Jones JL, Aly HM, Crescenzo DG, Wallace RB, Hopkins RA: Inhibition of adenosine deaminase and nucleoside transport: Utility in a model of homograft cardiac valve preimplantation processing. J Thorac Cardiovasc Surg 1993;105:1095–1105.PubMedGoogle Scholar
  29. 29.
    Zughaib ME, Abd-Elfattah AS, Jeroudi MO, Sun J-Z, Sekili S, Tang X-L, Bolli R: Augmentation of endogenous adenosine attenuates myocardial “stunning” independently of coronary flow or hemodynamic effects. Circulation 1993;88:[part 1]:2359–2369.PubMedGoogle Scholar
  30. 30.
    Abd-Elfattah AS, Ding M, Dyke CM, Dignan R, Wechsler AS: Attenuation of ventricular dysfunction “stunning” following normothermic ischemia and hypothermic cardioplegic arrest by augmentation of endogenous adenine nucleosides [abstract]. Circulation 1992;86(Suppl I):I-103.Google Scholar
  31. 31.
    Walsh RS, Abd-Elfattah AS, Daly JJF, Wechsler AS, Downey J: Selective blockade of nucleoside transport channels prevents preconditioning of rabbit myocardium: Surg Forum 1993;XLIV:234–236.Google Scholar
  32. 32.
    Walsh R, Abd-Elfattah AS, Daly JJF, Wechsler AS, Downey JM: Nucleoside transport inhibition prevents ischemic preconditioning [abstract]. Circulation 1993;88[Part 2]:1–432.Google Scholar
  33. 33.
    Abd-Elfattah AS, Wechsler AS: Protection of the stunned myocardium: Selective nucleoside transport blocker administered after 20 minutes of ischemia augments recovery of ventricular function. Circulation 1993;88[part 2]:336–343.Google Scholar
  34. 34.
    Abd-Elfattah AS, Jessen ME, Wechsler AS: Nucloside trapping during reperfusion prevents ventricular dysfunction“stunning,” in absence of adenosine: Possible separation between ischemic and reperfusion injury. J Thorac Cardiovasvc Surg 1994;108:269–278Google Scholar
  35. 35.
    Chang-Chun C, Masuda M, Szabo Z, Szerafin T, Scecsi J, Van Belle H, Flameng W: Nucleoside transport inhibitor lidoflazine induced cardioprotection during intermittent aortic cross-clamping. J Thorac Cardiovasc Surg 1992;104:1602–1609.PubMedGoogle Scholar
  36. 36.
    Flameng W, Daenen W, Borgers M, Thone F, Xhonneux R, van de Waters A, Van Belle H: Cardioprotective effects of lidoflazine during lh of normothermic global ischemia. Circulation 1981;64:796–807.PubMedCrossRefGoogle Scholar
  37. 37.
    Flameng W, Xhonneux R, Van Belle H, van de Waters A, Wouters L, Wijnants J, Thone’ F, Van Deale P, Janssen PA: Cardioprotective effects of mioflazine during lh normothermic global ischemia in the canine heart. Cardiovasc Res 1984;18:528–537.PubMedCrossRefGoogle Scholar
  38. 38.
    Liu GS, Borgers M, Xhonneux R, Van Overloop P, Thone F, Wouters L, Leijssen L; Evaluation of protective effects of lidoflazine and mioflazine in cardiac ischemia. Drug Dev Res 1986;8:407–416.CrossRefGoogle Scholar
  39. 39.
    Gliftanes M, Qiu Y. Van Belle H, Hearse DJ. Metabolic and functional effects of the nucleoside transport inhibitor R75231 in ischaemic and blood perfused rabbit heart. Cardiovasc Res 1993;27:90–95.CrossRefGoogle Scholar
  40. 40.
    Flameng W, Chen CC, Mubagwa K: Accumulation of endogenous adenosine by nucleoside transport inhibition failed to protect the ischemic myocardium [abstract]. J Mol Cell Cardiol 1992;24(Suppl II):S:14.Google Scholar
  41. 41.
    Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiocavasc Res 1993;27:68–76.CrossRefGoogle Scholar
  42. 42.
    Buchwald A, Ito BR, Schaper W: Influence of mioflazine on canine coronary blood flow and on adenine nucleotide and nucleoside content under normal and ischemic conditions. J Cardiovasc Pharmacol 1987;10:213–221.PubMedCrossRefGoogle Scholar
  43. 43.
    Zuh Q, Chen S, Zou C: Protective effects of an adenosine deaminase inhibitor on ischemia- reperfusion injury in isolated rat heart. Am J Physiol 1990;259:H835–H838.Google Scholar
  44. 44.
    Boiling SF, Bies LE, Bove EL, Gallgher KP: Augmenting intracellular adenosine improves myocardial recovery. J Thorac Cardiovasc Surg 1990;99:469–474.Google Scholar
  45. 45.
    Dorheim TA, Hoffman A, Van Wylen DGL, Mentzer RM Jn Enhanced interstitial fluid adenosine attenuates myocardial stunning. J Surg Res 1990;110:136–140.Google Scholar
  46. 46.
    Takeo S, Tanonaka K, Tazuma Y, Fukao N, Yoshikawa C, Fukumoto T, Tanaka T: Diltiazem and verapamil reduce the loss of adenine nucleotide metabolites from hypoxic hearts. J Mol Cell Cardiol 1988;20:443–456.PubMedCrossRefGoogle Scholar
  47. 47.
    Tosaki A, Szekeres L, Hearse DJ: Diltiazem and the reduction of reperfusion-induced arrhythmias in the rat: Protection is secondary to modification of ischemic injury and the heart rate. J Mol Cell Cardiol 1987; 19(5):441–451.PubMedCrossRefGoogle Scholar
  48. 48.
    Belloni FL, Liang BC, Gerritsen ME: Effect of alkylxanthines and calcium antagonists on adenosine uptake by cultured rabbit coronary microvascular endothelium. Pharmacology 1987;35:1–15.PubMedCrossRefGoogle Scholar
  49. 49.
    Moreyra BE, Gelpi RJ, Mosca SM, Cingolani BE: Chronic administration of nicardipine attenuates myocardial stunning in isolated rabbit hearts. J Mol Cell Cardiol 1994;26:979–984.PubMedCrossRefGoogle Scholar
  50. 50.
    Tibi PR, Patti CS, Pearce FJ, Hicks GL: Deleterious effects of dipyridamole during reperfusion of ischemic myocardium. Surgery 1985; 36:255–258.Google Scholar
  51. 51.
    Bunag RD, Douglas CR, Imau S, Berne RM: Influence of a pyrimidopyridine derivative on deamination of adenosine by blood. Circ Res 1964;15:83–88.PubMedGoogle Scholar
  52. 52.
    Knabb R, Gidday JM, Ely SW, Rubio R, Berne RM. Effects of dipyridamole on myocardial adenosine and reactive hyperemia. Am J Physiol 1984;247:H804–810.PubMedGoogle Scholar
  53. 53.
    Fredholm BB, Hedqvist P, Vernet L: Effect of theophylline and other durgs on rabbit renal cyclic nucleotide phosphodiesterase, 5′-nucleotidase and adenosine deaminase. Biochem Pharmacol 1978;27:2845–2850.PubMedCrossRefGoogle Scholar
  54. 54.
    Bukoski RD, Sparks HV: Adenosine production and release by adult rat cardiomyocytes. J Mol Cell Cardiol 1986;18:595–605.PubMedCrossRefGoogle Scholar
  55. 55.
    Kenakin TP, Leighton HJ: Methods used in adenosine research. In: Paton DM, editor, Methods in Pharmacology. London: Taylor& Francis 1988:251–258.Google Scholar
  56. 56.
    Van Belle H: In vivo effects of inhibitors of adenosine uptake. In: Paton DM, ed, Adenosine and adenine nucleotides: Physiology and Pharmacology: a specific inhibitory mechanism of high affinity probes. J Cell Ohysiol 1977;92:186–202.Google Scholar
  57. 57.
    Nakagawa Y, Gudenzi M, Mustafa SJ: Calcium entry blocking activity of dilazep in dog coronary artery. Pharmacol 1986;33:148–156.CrossRefGoogle Scholar
  58. 58.
    Borgers M: The role of the sarcolemma-glycocalyx complex in myocardial cell function. In: DeBakey, Gotto, editors, Factors influencing the course of myocardial ischemia. Elsevier Science Publishers.Google Scholar
  59. 59.
    Baer HP, Serigense V, Ogbundue POJ, Moorji A Mioflazine derivatives: their potential as in vivo nucleoside transport inhibitors and components and antiparasitic combination treatment. In Imai S, Nakazawa M, edis. Role of adenosine and adenine nucleotides in the biological systems. 1991, Elsevier Science Publishers BV, Amesterdam, New York, pp 161–170.Google Scholar
  60. 60.
    Aronow B, Ullman B. Role of the nucleoside transport function in the transport and salvage of purine nucleobases. J Biol Chem 1986;261:204–2019.Google Scholar
  61. 61.
    Plagemann PGW, Wohlhueter RM. S49 mouse lymphoma cells are deficient in hypoxanthine transport. Biochim Biophys Acta 1986;855:25–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Plagemann PGW, Wohlhueter RM. hypoxanthine transport in mammalian cells: cell typespecific differences in sensitivity to inhibition by dipyridamole and uridine. J Memr Biol 1984;81:255–262.CrossRefGoogle Scholar
  63. 63.
    Betz AL. Identification of hypoxanthine transport and xanthine oxidase activity in brain capillaries. J Neurochem Res 1985;44:574–579.CrossRefGoogle Scholar
  64. 64.
    Spector R. Hypoxanthine transport through the blood-brain barrier. Neurochem Res 1987;21:791–796.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Anwar S. A. Abd-Elfattah
    • 1
  • Samir Mardini
    • 1
  • Jian-Hua Guo
    • 1
  • Mohanad I. Shehab
    • 1
  • Nashaat El-Singaby
    • 1
  • Shin-Ping Gao
    • 1
  • El-Mostafa El-Guessab
    • 1
  1. 1.Division of Cardiothoracic Surgery, Department of Surgery, Medical College of VirginiaVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations